Latest 10-K annual reports

Espey Mfg. & Electronics Corp. announced a 4.95% increase in net sales for fiscal year 2026, reaching $46.12 million, with net income rising to $11.18 million.

Marwynn Holdings, Inc. has filed an amendment to its 2026 annual report to correct typographical errors in the executive compensation section.

Aytu BioPharma's fiscal year 2026 results show a net revenue decrease of 13.3% to $57.6 million, driven by declines in its ADHD and Pediatric portfolios, while launching its new MDD treatment, EXXUA.

Readvantage Corp. filed its annual 10-K for fiscal year 2026, detailing revenue growth but also significant net losses and material weaknesses in internal controls.

Thor Industries announced its fiscal year 2026 results, showing a slight increase in net sales but a decrease in gross profit, impacted by product mix and rising material costs.

AiRWA Inc. announced its fiscal year 2026 results, highlighting a significant increase in revenue driven by acquisitions and new business lines, but also reporting a substantial net loss and increased operating expenses.

Thunder Power Holdings, Inc. files an amended annual report highlighting material weaknesses in internal controls, ongoing losses, and the delisting of its common stock from Nasdaq, signaling significant financial and operational challenges.

AnaptysBio's transition report highlights significant revenue growth from Jemperli sales, driven by GSK's commercialization efforts, alongside strategic updates including a recent business separation.

Bloomia Holdings, Inc. (TULP) disclosed substantial goodwill and intangible asset impairments totaling over $13 million, alongside a significant net loss for the fiscal year ended June 30, 2026, while also addressing covenant breaches with its lender.

Advanced Oxygen Technologies, Inc. (AOXY) reported increased revenues for the fiscal year ended June 30, 2026, primarily driven by its real estate lease segment, though the company continues to face challenges with minimal overall revenue and a working capital deficit.

Neuphoria Therapeutics Inc. reports significant restructuring, discontinuation of its BNC210 social anxiety disorder program, and a substantial goodwill impairment, while advancing a proposed merger with Scancell Holdings plc.

The Marygold Companies, Inc. (MGLD) filed its annual report for fiscal year 2026, detailing an 8% revenue increase driven by its fund management segment, but also reporting a net loss of $4.4 million and significant impairment charges.

5E Advanced Materials, Inc. disclosed substantial doubt about its ability to continue as a going concern in its 10-K filing, citing significant losses and the need for substantial additional financing, even as it progresses its Fort Cady Project and pursues an acquisition.

Upexi, Inc. filed its annual 10-K report for the fiscal year ended June 30, 2026, detailing a significant strategic pivot towards a digital asset treasury, primarily focused on Solana (SOL), alongside a substantial net loss and ongoing legal disputes.

Paramount Gold Nevada Corp. has filed its annual report for the fiscal year ended June 30, 2026, detailing its exploration and development activities, financial condition, and forward-looking plans, while acknowledging substantial doubt about its ability to continue as a going concern.

The VanEck BNB ETF (VBNB) filing outlines the structure of its shares, operational details, and extensively details the significant risks associated with BNB, its ecosystem, and the broader digital asset market.

Aeluma, Inc. filed its annual report for the fiscal year ended June 30, 2026, detailing progress in technology development and customer engagement, while acknowledging ongoing operational and financial challenges.

Evolution Petroleum Corporation announced an interim increase to its credit facility and the acquisition of Permian Basin mineral interests, funded by a concurrent equity offering.

Marathon Bancorp, Inc. announced a substantial increase in net income for the fiscal year ended June 30, 2026, driven by robust net interest income and strategic loan portfolio growth.

Karbon-X Corp. announced its fiscal year 2026 results, showcasing a significant increase in revenue to $55.86 million but also reporting a net loss of $13.59 million and highlighting substantial financial risks.

Transglobal Management Group, Inc. has shifted its primary focus to the golf industry following the acquisition of GetGolf, LLC, while reporting significant accumulated deficits and ongoing operational losses.

Ispire Technology Inc. announced its fiscal year 2026 results, reporting a significant decrease in revenue and a continued net loss, impacted by market challenges and regulatory uncertainties.

Londax Corp. filed its annual report for the fiscal year ended May 31, 2026, detailing a significant revenue decrease, a substantial net loss, and ongoing going concern uncertainties, while also announcing a post-year-end change in control and a strategic pivot towards AI and digital infrastructure.

Longevity Diversified Holdings, Inc. (LGVT) filed its annual report, detailing its status as a shell company actively seeking a merger or acquisition, with no current operations or revenue and significant going concern risks.

Forgent Power Solutions, Inc. (FPS) filed its Form 10-K for the fiscal year ended June 30, 2026, reporting substantial revenue growth driven by increased demand in data center and grid markets, alongside significant expansion of manufacturing capacity.

Laredo Oil, Inc. filed its annual report highlighting persistent operating losses, a material weakness in financial controls, and substantial debt, while continuing to pursue its proprietary Underground Gravity Drainage (UGD) technology.

Radiant Logistics, Inc. filed its annual report, detailing a 3.3% increase in transportation revenue and improved value-added services margins, while acknowledging persistent economic and trade uncertainties.

Wewards, Inc. reported no revenue for the fiscal year ended May 31, 2026, and faces substantial doubt regarding its ability to continue as a going concern, though a significant debt forgiveness provided some financial relief.

Benitec Biopharma Inc. filed its annual report for the fiscal year ended June 30, 2026, detailing ongoing clinical development of its OPMD therapeutic, BB-301, and its financial position, which remains heavily reliant on future capital raises.

The Hain Celestial Group, Inc. filed its annual report for fiscal year 2026, detailing significant net losses, substantial asset impairments, and ongoing efforts to manage its debt obligations and strategic portfolio review.